Neurothera Labs (FRA:C0A) Total Equity: €0.55 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C0A Neurothera Labs Inc FRA:C0A
32 GF Score
Price €0.15
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs Total Equity?

Neurothera Labs FRA:C0A +0.34% 32 Total Equity is €0.55 Mil as of Dec. 2025. GuruFocus rates FRA:C0A with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Neurothera Labs's total equity for the quarter that ended in Dec. 2025 was €0.55 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Neurothera Labs Total Equity Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs Total Equity Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Total Equity
0.09 0.94 0.88 0.81 0.62

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.62 0.59 0.55 0.55
FRA:C0A
32GF Score
Neurothera Labs Inc FRA:C0A
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Neurothera Labs's Total Equity for the fiscal year that ended in Jan. 2025 is calculated as

Total Equity=Total Assets(Q: Jan. 2025 )-Total Liabilities(Q: Jan. 2025 )
=0.721-0.104
=0.62

Neurothera Labs's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2.59-2.037
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €0.55 Mil mean?
Neurothera Labs (FRA:C0A) has a Total Equity of €0.55 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Neurothera Labs and its competitors.
Is Neurothera Labs' Total Equity too high?
Neurothera Labs' current Total Equity is €0.55 Mil. Overall, Neurothera Labs has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' Total Equity compare to LLY and JNJ?
Neurothera Labs' Total Equity of €0.55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Neurothera Labs and its competitors. Neurothera Labs's current Total Equity is €0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (FRA:C0A) has a current Total Equity of €0.55 Mil. The current Total Equity is €0.55 Mil. Neurothera Labs' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Neurothera Labs (FRA:C0A), the current Total Equity is €0.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurothera Labs Business Description

Other Exchanges NTLX:Canada
Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score

Get the complete analysis for FRA:C0A

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price